Compare HLP & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLP | IPHA |
|---|---|---|
| Founded | 2021 | 1999 |
| Country | China | France |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.2M | 165.3M |
| IPO Year | 2021 | 2014 |
| Metric | HLP | IPHA |
|---|---|---|
| Price | $2.54 | $1.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.67 |
| AVG Volume (30 Days) | ★ 116.6K | 51.6K |
| Earning Date | 10-20-2026 | 09-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $390.56 |
| Revenue Next Year | N/A | $143.06 |
| P/E Ratio | $51.63 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.34 | $1.18 |
| 52 Week High | $2.61 | $2.71 |
| Indicator | HLP | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 82.71 | 27.90 |
| Support Level | $0.78 | $1.34 |
| Resistance Level | N/A | $1.57 |
| Average True Range (ATR) | 0.15 | 0.10 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 86.57 | 0.00 |
Hongli Group Inc is an offshore holding company. Through its subsidiaries, it is engaged in the cold-rolled steel profile manufacturing in China. Its main business operation focuses on the design, production, deep processing, and sales of custom-made profiles for machinery and equipment in a variety of sectors, including but not limited to mining and excavation, construction, agriculture, and transportation industries. The group operates in a single segment, which manufactures and sells agricultural machinery cab assemblies, construction machinery cab assemblies, excavator cab assemblies, and special-shaped steel pipes. It generates the majority of its reveneue from PRC.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.